Friday, 1 February 2019

Endovascular Aneurysm Repair Devices Market Trends, Analysis and Review during 2018 To 2023

Market Scenario
Global endovascular aneurysm repair devices market is likely to grow significantly over the forecast period. It is estimated that the global endovascular aneurysm repair devices market is expected to record a CAGR ~ 6.4 % during the forecast period of 2018 to 2023. The weakening and bulging of the aorta is called aortic aneurysm. The bulging can cause a leak that spills blood into the body. It can direct the blood flow away from the organs and tissues, causing severe complications, such as kidney damage, heart attacks, stroke, and even death. Thus, endovascular repair can be done by placing a stent-graft in an aneurysm through a small hole in the blood vessels in the groin area.
Numerous factors such as reduced recovery times, low-cost hospitalization charges, and technological advancements in repair devices are expected to drive the growth of the market. For instance, in March 2017, Terumo Corporation completed the acquisition of Bolton Medical, Inc. with the acquired company being a leading innovator in thoracic and abdominal stent graft systems, Terumo Corporation aimed to strengthen its growth in vascular graft segment.
However, stringent government regulation, the preferable alternative of open surgery and various complications such as endoleaks and infections may hamper the market growth during the assessment period.
Key players
  • Cardiatis SA,
  • Cardinal Health,
  • Cook Medical LLC,
  • Endologix, INC.,
  • Jotec GmbH,
  • Medtronic plc,
  • Terumo Corporation,
  • L. Gore & Associates, Inc.,
  • BiFlow Medical Ltd,
  • Boston Scientific Corporation,
  • Braile Biomédica,
  • Endoluminal Sciences Pty Ltd,
  • Endospan Ltd.,
  • Getinge AB,
  • Lemaitre Vascular Inc.
Segmentation
The global endovascular aneurysm repair devices market has been segmented into indication, site, anatomy, and products.
The market, on the basis of indication, has been segmented into the abdominal aortic aneurysm, thoracic aortic aneurysm and others.
The market, based on thoracic aortic aneurysm, has been further segmented into ascending aortic aneurysm, descending aortic aneurysm, thoracoabdominal aortic aneurysm, and thoracic arch aortic aneurysm.
The market, on the basis of the site, has been segmented into infrarenal and pararenal.
The market, based on pararenal site, has been sub-segmented into juxtarenal and suprarenal.
The market, on the basis of anatomy, has been segmented into traditional and complex.
The market, on the basis of products, has been segmented into percutaneous EVAR, fenestrated EVAR, aortic stents and TAA grafts, and others.
Regional Market Summary
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The endovascular aneurysm repair devices market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The Americas is expected to dominate the global endovascular aneurysm repair devices market owing to increasing geriatric population, and well-developed healthcare sector. With the increase in the geriatric population, the prevalence of aneurysms is also expected to rise. The Centers for Disease Control and Prevention (CDC) ranks abdominal aortic aneurysm as one of the top 15 causes of mortality in the United States, but only for those between 85 and 89 years. According to the Centers for Disease Control and Prevention, aortic aneurysms were the primary cause of 9,863 deaths in 2014 in the US.
Europe is expected to hold the second largest position in the global endovascular aneurysm repair devices market. The market growth in this region is attributed to the growing prevalence of aneurysms, availability of funds for research, and favorable reimbursement scenario.
On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to the growing government initiatives for the healthcare sector.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.
Browse Complete 100 Pages Premium Research Report Enabled with 110 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/endovascular-aneurysm-repair-devices-market-6485

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Veterinary Imaging Market in depth study and analysis published, 2018

Market Scenario
Pet healthcare is trending globally with the focus shifting towards improving veterinary capabilities on all fronts. Veterinary imaging remains one of the key focus areas as animal care providers, veterinaries and animal research institutes increase their efforts towards developing superior veterinary imaging technologies. The global veterinary imaging market was valued at USD 1247.61 Mn in 2017 and is expected to surpass a valuation of USD 1800 Mn by the end of 2023. The arrival of high-quality, dedicated imaging solutions that are meeting various animal care needs characterizes the growing interest of healthcare technology companies in the particular space. A number of reputable animal healthcare bands have stepped up their efforts in developing veterinary imaging systems that are not only efficient but also cost-effective.
Over the years, demand for medical diagnostics and imaging for animals has increased significantly. This can be attributed to the increased level of awareness about importance of good health of animal companions among owners. Greater emphases on keeping both farm animals and companion animals in better health condition is reflecting favourably on the global veterinary.
According to the Maine Center for Disease Control & Prevention, close to three-fourths of emerging infectious diseases that affect humans originate in animals. With rising incidences of zoonotic diseases over the past decade or so, has raised the requirement for the development of appropriate diagnostic measures. Moreover, with pet adoption rising, animals are increasingly becoming a member of the family, and as such, pet owners and animal enthusiasts who work in animal rescue have compelled demand for advancements in diagnostic technology such as veterinary imaging for the detection of chronic diseases. Pet insurance often offers up to 80% reimbursement, and due to the growing demand for advanced diagnostics, pet owners are spending on insurance for their animal companions. The North American Pet Health Insurance Association (NAPHIA) has recorded a 17.2% increase in pet health insurance from 2014 to 2015.
Without pet insurance, however, procedures that involve veterinary imaging modalities are expensive and as such are expected to hamper market growth. The University of Illinois published in a report which found that procedural cost ranged between USD 878 to USD 1,461 depending on the site and inclusion of contrast. However, due to the factors mentioned above and the unrealized potential in the market, regulatory authorities such as the FDA have proposed various guidelines of imaging accuracy which have compelled competitors in the market, both new and existing, to develop innovative products and services which meet these guidelines, thus creating new avenues for growth during the assessment period. 
Competitive Tracking
Key players in the global veterinary imaging market that have been analyzed in the report include Fujifilm Holding Corporation, Heska Corporation, Idexx Laboratory Inc, and Canon. Other players include Hallmarq Veterinary Imaging Ltd., Carestream Health, General Electric and others. Market strategies most employed by these competitors include product innovation and investments in R&D pipeline.
Segmentation
MRFR’s report offers a detailed segmental analysis of the market based on product type, by animal type, by therapeutic area, by end users, and by region. By product type, the market is segmented into veterinary imaging instruments, veterinary imaging reagents, and veterinary imaging software. The veterinary imaging instruments segment currently holds the maximum share of the global veterinary imaging market. Conventional imaging systems such as X-ray, CT, ultrasound (US), and MRI are mainly used to evaluate the anatomy but are unable to diagnose any change at the molecular level.
However, with the increased focus towards innovations in the field of veterinary medicine, several new biological imaging reagents have surfaced of late. On the basis of animal type, the market is segmented into small companion animals, large animals, and others. In 2017, the small companion animals segment accounted for the highest market share. Rising trend of pet ownership, greater awareness about pet care and increased expenditure on pet health are some of the factors linked with the segment’s growth.
By therapeutics areas, the market is segmented into orthopedics & traumatology, cardiology, neurology, oncology and others. The orthopedics & traumatology segment is expected to remain highly attractive during the assessment period.  Bone injuries are more common among animals, which characterises the prominence of the orthopedics & traumatology segment. In addition, growing demand for accurate diagnostic solutions and availability of cutting-edge animal care facilities is also driving the segment’s growth.
On the basis of the end-user, the market is segmented into hospitals & clinics, academic institutes, and others. The hospitals & clinics segment held the largest segment of the market in 2017 and is likely to retain its top position over 2023. At the same time, use of veterinary imaging in academic institutes is also growing at a rapid pace. The academic institutes segment is slated to witness a relatively higher CAGR during the assessment period.
Regional Analysis
Led by North America, The Americas have the largest share of the global market. The region is witnessing a rising demand for pet insurance as pet owners are becoming more invested in their pets’ health. The rapid adoption of innovative technology offerings in the region is responsible for its leading position in the veterinary imaging market. Europe, with its inclusion of developed countries such as Germany, France, and the U.K. accounts for the second largest market share due to the presence of prominent market players and supportive government initiatives toward pet insurance and pet healthcare.
The Asia-Pacific is set to grow at the most rapid pace with countries such as Japan, China, and India taking the lead. The growing prevalence of nuclear families with a tendency toward pet adoption and increasing investments in pet care have prompted international players to establish their presence in these countries in an effort to tap the potential this region carries.
Browse Complete 138 Pages Premium Research Report Enabled with 171 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/veterinary-imaging-market-2919

         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Wednesday, 30 January 2019

Verrucous Carcinoma Market 2018 Analysis, Opportunities and Forecast to 2023

Verrucous carcinoma (VC) is a rare type of squamous cell carcinoma and is categorized under head and neck cancer.  It is mainly caused due to the chewing of tobacco or snuffing it orally. It is also called as snuff dipper's cancer. Verrucous carcinoma most commonly occurs at oral sites but is also observed in head and neck genital locations. It is mainly observed in males than in females and is found in the age group of 50 to 80 years. The key factor responsible for influencing this market is the increasing prevalence of oral cancer. It may also be caused due to lifestyle factors such as smoking tobacco or marijuana, alcohol consumption, and others. Other key factors such as a change to sedentary lifestyle, growing consumption of alcohol, increasing tobacco users of dip, snuff, increase in smoking, rising family history of cancer prevalence, and increasing prevalence of sexually transmitted diseases by human papillomavirus are contributing towards the growth of the market. According to the World Health Organization in 2015, globally 1.1 billion people smoked tobacco. This is expected to provide favorable backgrounds for market growth during the forecast period.
However, factors such as the high cost of surgical procedures, expensive chemotherapy treatments, and side effects associated with treatments are expected to restrict the market growth during the forecast period.
Key players
Some of the key players in the global verrucous carcinoma market are Bristol-Myers Squibb Company (US) Qilu Pharmaceutical Co., Ltd. (Asia Pacific), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company. (US), F. Hoffmann-La Roche Ltd (Europe), Merck & Co., Inc. (US), Novartis AG (Europe), Pfizer Inc. (US), and others.
Segmentation
The global verrucous carcinoma market is segmented on the basis of diagnosis, treatment, and end-user. The verrucous carcinoma market, by diagnosis, is categorized into biopsy, endoscopy, and imaging tests. Imaging tests are categorized into computerized tomography scans, magnetic resonance imaging, and positron emission tomography scans. On the basis of treatment, the market is segmented into surgery, radiation therapy, chemotherapy, and targeted drug therapy. The surgery category consists of surgical excision and mohs micrographic surgery. Chemotherapy consists of bleomycin, 5-fluorouracil, cisplatin, methotrexate, and others. On the basis of end-user, the market is segmented into hospitals and clinics, ambulatory surgical centers, diagnostic centers, research centers, and others.
On the basis of region, the global verrucous carcinoma market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.
Regional Market Summary
It is estimated that North America dominated the global verrucous carcinoma market owing to the increasing innovations in clinical practice, cancer research, and access to cancer treatment in this region. The American Cancer Society in August 2018 granted USD 15,866,878 for head and neck cancer research projects. This influences the market growth in this region
According to the World Health Organization’s Fact Sheet on Tobacco and Oral Health (2018), Europe has the highest prevalence of tobacco smoking among adults that is 28% of adults in Europe are engaged in tobacco smoking. Such a high prevalence of smoking in this region facilitates the market growth. Europe stood second largest in the verrucous carcinoma market owing to the increasing use of tobacco.
Asia-Pacific was projected to be the fastest growing region for the global verrucous carcinoma market in 2017. The market is expected to witness growth owing to the rising prevalence of oral cancer, changing lifestyle, and increasing tobacco use within the population. The Center for Cancer Control and Information Services estimated 15,600 cases of oral cavity and pharynx cancer in 2017 in Japan. Such a high incidence of oral cancer favors the market growth in this region.
The Middle East and Africa holds the least share in the global verrucous carcinoma market due to the presence of poor health expenditure and economically diverse countries. However, the market is expected to witness growth due to increasing cancer care programs in the Middle East.
Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/verrucous-carcinoma-market-6367

         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Distraction Osteogenesis Devices Market Growth and Restrain Factors Analysis By 2023

Market Scenario:
Global Distraction Osteogenesis Devices Market is expected to grow significantly over the forecast period. Distraction osteogenesis is the biological process of the new bone formation between bone segments which are gradually separated by incremental traction.  
Numerous factors such as advancements in distractor devices such as miniaturized internal and external devices, easily placeable and easy handling are expected to drive the growth of the market. For instance, In May 2018, DePuy Synthes, a part of the Johnson & Johnson Medical Devices Companies, announced an exclusive agreement in the US between DePuy Synthes Sales, Inc. and Prosidyan to promote the Fibergraft family of products, a line of synthetic bone graft materials which are ultra-porous, designed for ease of use, and have been engineered for ideal resorption in clinical use during spine fusion surgery. By adding Fibergraft to its offerings, DePuy Synthes will further enhance the company’s portfolio of biomaterials and distractors.
Moreover, various risks such as failure to follow the distraction protocol and damages to nerves hamper the market growth during the assessment period.
Segmentation
The Global Distraction Osteogenesis Devices Market has been segmented into device type, age, application, and end-user.
The market, based on device type, has been segmented into mandibular distraction devices, palatal distraction devices, alveolar distraction devices, craniofacial distraction devices, Lefort distraction devices, small bone distraction devices, and others. The market, based on craniofacial distraction devices, has been further segmented into external and internal distractors. The market, based on external distractors is further classified into unidirectional distractors, bidirectional distractors, and multiplanar distractors whereas the market, based on, internal distractors can be classified into tooth-borne distractors, bone-borne distractors, and hybrid distractors. The market, by age, has been segmented into pediatrics and adults. The market, by application, has been segmented into dentistry, podiatry, orthopedics, and others. The market, by end-user, has been segmented into hospitals, orthopedic clinics, and others.
Key players
Johnson & Johnson Services, Inc., Zimmer Biomet Holdings, Inc., Stryker Corporation, KLS Martin Group, Osteomed, Acumed LLC, Jeil Medical Corporation, Ningbo Cibei Medical Treatment Appliance Co., Ltd. Ortho Max Manufacturing Company Pvt. Ltd., Ortho Care and Titamed are some of the key players in the global distraction osteogenesis devices market.
Regional Market Summary
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Distraction Osteogenesis Devices Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European distraction osteogenesis devices market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Distraction Osteogenesis Devices Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The distraction osteogenesis devices market in the Middle East & Africa has been segmented into the Middle East and Africa.
Geographically, North America is expected to dominate the global distraction osteogenesis devices market owing to increasing number of procedures for treating facial abnormalities in the US. Also, most of the key players have their research and development teams working in this field in the US which in turn increases the awareness among the people about the technique in this region.
The European market is expected to be the second-largest due to increase in initiatives taken by public and private organizations in this field.
Browse Complete 90 Pages Premium Research Report Enabled with 94 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/distraction-osteogenesis-devices-market-6392  
         
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Dercum’s Disease Market Analysis 2018 (By Segment, Key Players and Applications) and Forecasts To 2023

Market Scenario
The global Dercum’s Disease treatment market is expected to register a significant growth during the forecast period (2018–2023).
Legg-calve-perthes is a disease which occurs when the blood supply to the femoral head (upper end of the thigh bone) which fits in the hip socket temporarily stops to flow. As an outcome, the femoral head is no longer round and does not move smoothly in the hip socket, resulting in hip pain and constrained leg movements.
Dercum’s Disease (LCPD) generally occurs in children of age 4 to 10 years. Individuals suffering from the disease go on developing a painful joint disorder called as osteoarthritis in the hips at an early age. Individuals suffering from the Dercum’s Disease are often short compared to healthy individuals due to bone anomalies.
Key players
Pfizer, Inc., Abbvie, Inc., Johnson & Johnson, GlaxoSmithKline Plc, Merck & Co., Inc., Novartis,Hoffman, La Roche AG, Eli Lily and Company, AstraZeneca PLC, Amgen, Valeant Pharmaceuticals, Syneron Medical, St. Jude Medical Inc. and Alimed, Inc. are some players in the global dercum’s disease market.
Segmentation
The global dercum’s disease market has been segmented into treatment, distribution channel, and end-user.
The market, on the basis of treatment, has been segmented into surgery, medication, liposuction, electrotherapy, acupuncture, and others. The medication segment has been further segmented into diuretics, non-steroidal anti-inflammatory drugs, corticosteroids, and others.
The market, by distribution channel, has been segmented into retail pharmacies, hospital pharmacies, and others.
The market, by end-user, has been segmented into hospital & clinics, ambulatory surgical centers, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The dercum’s disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European dercum’s disease market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 
The dercum’s disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The dercum’s disease market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global dercum’s disease market owing to a well-established healthcare sector, rising prevalence of rare diseases, and growing healthcare expenditure. According to the data published in the National Center for Biotechnology Information (NCBI) in 2017, about 25 to 30 million American population live with a rare disease. Additionally, favorable reimbursement scenario and a relatively large number of research and development (R&D) activities contribute to the growth of the market. According to the Centers for Disease Control and Prevention (CDC), in the US, the total national health expenditure was USD 3.2 trillion in the year 2015.
Europe is expected to hold the second largest position in the global dercum’s disease market. The market growth in this region is attributed to the availability of funds for research and increasing healthcare expenditure. According to the Office for National Statistics, gross domestic expenditure on research and development (R&D) was Euro 33.1 billion (USD 35.2 billion) in 2016.
The dercum’s disease market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region in the market due to the growing disposable income, continuously developing economies, and increasing government funding for the healthcare sector. Additionally, regional expansions by market players in the region are considered to be contributing to the market growth.
The Middle East & Africa has the least market share in the global market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.
Browse Complete 90 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/dercums-disease-market-6350    

       
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Agnosia Treatment Market 2018–By Identifying the Key Market Segments and Key players holding market share

Market Scenario
Agnosia is a rare neurological condition in which an individual may face difficulty to process sensory information like recognizing a familiar person, sound or object. It is due to occurrence of lesions in the brain. Medical conditions such as dementia, stroke, head injury or any other neurological condition may lead to development of agnosia. Moreover, there are several conditions that may cause brain lesions and are associated with agnosia.
People suffering from agnosia can still interact with others normally. As such agnosia affects a single pathway when brain suffers a certain damage. The pathway might connect primary sensory areas that store information and knowledge. The primary sensory regions mainly include visual or auditory cortices. According to the World Health Organization (WHO) estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies.
Brain imaging techniques such as CT or MRI with or without angiographic protocols is required to characterize a central lesion such as hemorrhage, infarct or mass and also might check medical history of the patient and atrophy suggesting a degenerative disorder.
Many individuals suffering from agnosia can still retain their cognitive abilities, such as reading and basic math. The condition affects everyone differently but it can significantly impact the quality of life.
The cause of this disorders may precede the development of primary visual agnosia. Some causes of agnosia include diseases such as Alzheimer’s, Pick’s disease, Balint’s syndrome.  Alzheimer’s is a common, progressive, degenerative brain disorder affecting memory, thought, and language. Pick’s disease is also a degenerative neurological disorder that closely resemble the symptoms of Alzheimer’s disease. Balint’s syndrome is a rare neurological disorder characterized by the inability to voluntarily look at objects to the side. Individuals often cannot read, grasp or view one’s surroundings as a whole (simultanagnosia).
Some of the most probable causes of this disease are dementia, carbon monoxide poisoning, encephalitis, traumatic brain injuries and strokes. Physical examination is performed to detect any primary deficits in individual related to senses or inability to infer any test for agnosia.  According to WHO, the total number of people with dementia worldwide is projected to nearly double every 20 years, to 65.7 million in 2030 and 115.4 million in 2050. The total number of new cases of dementia each year is nearly 7.7 million worldwide, implying one new case every four seconds.
There is no specific treatment for agnosia. If doctors are able to identify the cause, the treatment will be tailored to the specific problem. For example, if an abscess is causing agnosia, the doctor may prescribe antibiotics and refer for a surgery to drain the abscess. Rehabilitation with speech or occupational therapists can help patients learn to compensate for their deficits.
Organizations such as the National Institute of Neurological Disorders and Stroke (NINDS) collects and disseminates research information related to neurological disorders. Furthermore, the National Organization for Rare Disorders (NORD) has a report for patients and families about this condition. NORD is a patient advocacy organization for individuals with rare diseases and the organizations that serve them.
The global market of agnosia treatment is expected to grow at a CAGR of approximately 7.2% during the forecast period 2017-2023.
Key Players
Some of key the players in the global agnosia treatment market are B. Braun Melsungen (Germany), Pfizer Inc. (U.S.),  Lupin ltd. (India), Fujifilm Holdings (Japan), GE Healthcare (U.S.), Siemens Healthcare(U.S.), Philips Healthcare (U.S.), F. Hoffmann-La Roche AG (Switzerland) , Aurobindo Pharma Ltd (India), Sandoz GmBH (Austria), Stellar- Bio Labs (India), Fresenius Kabi Ipsum SRL (Italy), Zhuhai United Laboratories Co Ltd (China), Cspc Zhongnuo Pharmaceutical Shijiazhuang Co Ltd (China), IPCA Labs ltd. (India) and others.
Segmentation
The agnosia treatment market is segmented on the basis of is segmented on the basis of diagnosis, causes, type, and treatment.
On the basis of diagnosis it is segmented into Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and others.
On the basis of causes it is segmented into Alzheimer's disease, Pick's disease, MELAS, Balint's syndrome.
On the basis of the type, it is segmented into auditory agnosia, gustatory agnosia, olfactory agnosia, tactile agnosia, visual agnosia, and others. Others is further segmented into prosopagnosia and anosognosia
On the basis of treatment, it is segmented into surgery, antibiotics for cerebral absess and radiation of brain tumor. Antibiotics for cerebral absess is further segmented into Ceftriaxone and Cefotaxime+metronidazole
Regional Analysis
The global agnosia treatment market consists of countries namely America, Europe, Asia Pacific, and the Middle East & Africa.
North America dominated the global agnosia treatment market owing to the increasing healthcare expenditure. The increasing incidence of accidents and brain injury is leading to development of new treatment methods are some of the driving factors responsible for the growth of the global agnosia treatment market.
Europe holds the second position in the global agnosia treatment owing to the government support for research & development and availability of funds for research. People with agnosia can benefit from speech and occupational therapy provided by the various European medical organisations such as Alzheimer Europe, and the European Conference on Visual Perception (ECVP) to learn how to deal with this impairment in their daily life.
Asia Pacific is the fastest growing agnosia treatment owing to the presence of rapidly developing healthcare technology, increasing stressful life, and high healthcare expenditure. Furthermore in the Middle East & Africa the spending for healthcare was also increased. The Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/agnosia-treatment-market-5045  

  
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Anoxia Market Growth and Restrain Factors Analysis By 2023

Market Scenario
Anoxia is a condition that occurs due to complete loss of oxygen in body or brain which leads to various cognitive problems, and disabilities. It is considered as a severe cause of hypoxia. The most common causes of anoxia are respiratory arrest, drowning, carbon monoxide inhalation, illegal drug use, brain tumors, heart arrhythmia, suffocation, compression of the trachea, heart attack, and many others. Anoxic brain injury is also known as hypoxic-anoxic injury (HAI) or cerebral hypoxia. There are different types of anoxia, and each has an internal, and external causes. For instance, anemic anoxia occurs when blood is unable to carry enough oxygen to keep organs functioning properly, whereas, stagnant anoxia occurs when blood doesn’t reach brain or other body parts properly. Cardiovascular events such as, heart attack, cardiac arrhythmia, heart failure, and stroke, are the most common causes of stagnant anoxia. Anoxic anoxia usually at high altitudes. According to a study published in the Neural Regeneration Research journal, it is found that the with the increasing altitude partial pressure of oxygen falls which results in anoxic challenge to the person ascending to high altitudes.
Short-term memory loss, poor performance in executive functions, anomia, and visual disturbances are the commonly known cognitive problems associated with anoxia, whereas, physical problems include ataxia (lack of coordination), apraxia (inability to do common tasks), movement disorders, quadriparesis, and headaches.
Notably, rising cases of cardiac arrest is the key factor driving the anoxia market. According to a study published in the Critical Care journal in 2017, it is found that hypoxic ischemic brain injury (HIBI) is an outcome of cardiac arrest. It is stated that HIBI is the major cause of death in 23% of out-of-hospital cardiac arrest, and in 68% of inpatient cardiac arrest.
Various other factors such as, increasing awareness among people, increasing government assistance, and improvement in regulatory framework continuously contribute to the growth of the global anoxia market.
Despite these drivers, there are some issues associated with anoxia market. Challenges in research and development, and poor healthcare system in low and middle income countries may hinder the growth of market to an extent.
It is estimated that anoxia market is expected to grow at a CAGR 5.4% during the forecast period of 2017-2023.
Segmentation
The anoxia market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, market is segmented into anemic anoxia, toxic anoxia, stagnant anoxia, and anoxic anoxia.
On the basis of diagnosis, market is classified into blood tests, MRI (magnetic resonance imaging), CT or CAT scan (computerized axial tomography), evoked potential tests, and EEG (electroencephalogram).
On the basis of treatment, market is classified into cardiopulmonary resuscitation (CPR), rehabilitation therapies, and medication. Rehabilitation therapies is further segmented into speech therapy physical therapy, occupational therapy, recreational therapy, and adaptive equipment training. Medication is also further classified into ammonia reducer, anticonvulsant, steroids, vitamin, and others.
On the basis of end-users, market is segmented into hospital & clinics, diagnostic centers, research institutes, rehabilitation Centers, and others.
Regional Analysis
The Americas dominate the anoxia market owing to the rise in awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.
Europe holds the second position in anoxia market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region.
Asia Pacific is the fastest growing anoxia market owing to the huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.
The Middle East & Africa has the lowest market for anoxia due to lack of technical knowledge and poor medical facilities.
Key Players
Some of key the players in the anoxia market are Pfizer, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc,, Cephalon Inc., Shire, UCB S.A, and others.
Browse Complete 85 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/anoxia-market-4989

        
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com